Werfen to Acquire Transfusion and Transplant Diagnostics Innovator for Around USD 2 Billion

Werfen (Barcelona, Spain) has agreed to acquire Immucor, Inc. (Norcross, GA, USA), a privately held corporation with a global presence in transfusion and transplant in vitro diagnostics, at a purchase price of approximately USD 2 billion. The acquisition will allow Werfen to expand its portfolio of Specialized Diagnostics solutions for hospitals and clinical laboratories. The transaction is expected to close during the first half of 2023, subject to customary regulatory approvals.

"As a global leader in the research, development, manufacturing and distribution of innovative, Specialized Diagnostics solutions for hospitals and clinical laboratories, Immucor is a natural fit with our existing business model," said Marc Rubiralta, President of Werfen. "We highly value Immucor's commitment to enhancing care for all patients in need of a transfusion or transplant. This fits squarely with our long-term vision and strategy, aligns with our focus, and complements Werfen's values."

"I am confident that by combining two complementary, outstanding Specialized Diagnostics companies, Werfen will expand its global presence with greater diversification, while successfully maintaining its focus on specialization," Rubiralta added.

"Immucor's expertise and innovations in transfusion and transplant diagnostics enable us to enter new markets and will help achieve our vision to be the preferred choice of the most advanced laboratory and point-of-care customers, globally," said Carlos Pascual, CEO of Werfen. "It will be a major milestone in the future of Werfen."

"As we look to the future, we are excited to grow our impact as part of Werfen, a company that shares our long-term vision and commitment to advancing patient care globally," said Avi Pelossof, CEO of Immucor. "As the value of diagnostics in the healthcare system grows, we are confident that Immucor will continue to innovate and succeed under Werfen's ownership."

Related Links:
Werfen
Immucor, Inc.